Loading…
Akanda Corp
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in AKAN.
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $10.29 | $112.61 | $2,477.48 | $8,389.64 | |
| P/S | 5.8x | 17.6x | — | 5.8x | 2.0x |
| P/B | — | — | 0.8x | — | 0.2x |
| EPS | -$14,899.95 | -$140.67 | -$32,275.07 | -$18,955.57 | |
| Profit margin | -7617.74% | -17690.19% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SHPHShuttle Pharmaceuticals Holdings, Inc. | $3.54 | 39.3x | 0.6x | — | -326.36% | $2.07M |
| IMCCIM Cannabis Corp. | $3.41 | — | — | — | — | $2.06M |
| SLXNSilexion Therapeutics Corp | $0.36 | — | 0.4x | — | — | $2.02M |
| EDVAEndovia Health Sciences, Inc. | $0.31 |
Akanda Corp., through its subsidiaries, operates as early-stage cannabis company in Mexico. It is involved in medical cannabis cultivation, manufacturing, and sale; and leasing and/or rental of fiber optic networks and telecommunication towers. The company is based in Toronto, Canada.
Company description provided by Yahoo Finance.
| — |
| -7617.74% |
| -445.00% |
| ROE | — | — | -95.78% | — | -43.34% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| — |
| — |
| — |
| $1.99M |
| VRAXVirax Biolabs Group Ltd | $2.82 | — | 0.2x | — | -78.65% | $2.25M |
| RNAZTranscode Therapeutics, Inc. | $2.18 | — | 1.6x | — | -59.28% | $2.31M |